Discover
CAMP
CAMP4 THERAPEUTICS CORPORATION
4.34
2 x 3.22
2 x 5.47
bid
ask
-
0.03
0.69%
2 @ 04:00 PM
4.34 +0.00 (0.00%)
| Ytd | -29.20% | |
| 1y | 221.48% |
4.17
day range
4.53
1.32
52 week range
7.75
| Open | 4.37 | Prev Close | 4.37 | Low | 4.17 | High | 4.53 | Mkt Cap | 225.36M |
| Vol | 146.14K | Avg Vol | 157.49K | EPS | -2.35 | P/E | N/A | Forward P/E | -2.52 |
| Beta | 1.89 | Short Ratio | 2.72 | Inst. Own | 42.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 4.26 | 200-d Avg | 4.33 | 1yr Est | 19.91 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-07-08 | 2024-05 | -0.92 | N/A | N/A | N/A |
| 2024-06-06 | 2024-02 | -3.22 | N/A | N/A | N/A |
| 2024-01-09 | 2023-11 | -2.3 | N/A | N/A | N/A |
| 2023-10-05 | 2023-08 | 0.46 | N/A | N/A | N/A |
| 2023-07-10 | 2023-05 | 0.92 | N/A | N/A | N/A |
| 2023-04-27 | 2023-02 | 0.23 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-05 | William Blair | Upgrade | Outperform | |
| 2024-11-05 | Leerink Partners | Upgrade | Outperform | |
| 2024-11-05 | JP Morgan | Upgrade | Overweight | |
| 2024-11-05 | Piper Sandler | Upgrade | Overweight |
Profile
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-14 | 5AM PARTNERS VI, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-10-14 | AH EQUITY PARTNERS BIO I, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-10-14 | ENAVATE SCIENCES GP, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-10-14 | HOLTZMAN STEVEN H | Director | 108.95K | Conversion of Exercise of derivative security |
| 2024-10-14 | MANDEL-BREHM JOSH | Chief Executive Officer | 272.36K | Conversion of Exercise of derivative security |
| 2024-10-14 | NASHAT AMIR H. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 227.30K | 1.72M | 1.13% |
| 2024-10-30 | Fidelity Growth Company Fund | 171.20K | 1.30M | 0.85% |
| 2024-10-30 | Fidelity Growth Company K6 Fund | 52.40K | 397.22K | 0.26% |
| 2024-10-30 | Fidelity Series Growth Company Fund | 43.50K | 329.73K | 0.22% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|
Split
| Split | Date |
|---|---|
| 1 : 23 | 2024-02-02 |
| 1 : 23 | 2024-02-01 |
| 2 : 1 | 1996-03-25 |